Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
American Journal of Health-System Pharmacy, Vol 58, Issue 4, 331-337
Copyright © 2001 by American Society of Health-System Pharmacists


Articles

ASHP therapeutic position statement on the identification and treatment of Helicobacter pylori-associated peptic ulcer disease in adults. Developed by the ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 11, 2000


ASHP supports the identification and treatment of H. pylori infection in appropriate patients as an effective method of reducing the morbidity and mortality associated with peptic ulcer disease. Successful and safe therapy requires extensive patient education and monitoring by qualified health care professionals to maximize patient understanding of and compliance with medication regimens and to minimize adverse events. Pharmacists are key to ensuring that patients use prescribed regimens appropriately so that H. pylori is eradicated and that clinical outcomes of associated peptic ulcer disease are optimal.
 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society of Health-System Pharmacists.